Filing Analysis
Regulation FD Disclosure
Filed Mar 05, 2026
LOW
Metagenomi Therapeutics, Inc. (MGX) furnished its financial results for the fiscal year ended December 31, 2025, and provided general business updates. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
Key Facts
- Announcement date: March 5, 2026
- Reporting period: Fiscal year ended December 31, 2025
- Filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits)
- The company is classified as an emerging growth company
- The report was signed by President and CEO Jian Irish, Ph.D., M.B.A.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.